COVID Vaccines: US FDA Should Play More Activist Role In Development Of Modified Formulations
Executive Summary
Advisory committee tells FDA that the agency, not vaccine manufacturers, should dictate the conversation around variants and reformulations; panelists also want better government research on immune correlates of protection ahead of any decision on a composition change.